CAR T for Leukemia Patients
With the discovery of the first gene therapy to be approved by the FDA, Penn Medicine is leading the world in immunotherapy research. Physicians at Penn and Children’s Hospital of Philadelphia have worked together to treat nearly 500 blood cancer patients in clinical trials for personalized cellular therapies.
Take a look at our frequently asked questions to learn more about personalized CAR T-cell therapy and who may be a candidate.
If you are an adult patient who has been diagnosed with acute lymphoblastic leukemia (ALL) and are interested in T cell therapies at Penn Medicine, please call 215-316-5127 for more information. For information about the Cancer Immunotherapy Program at CHOP, please call 267-426-0762.
Active Immunotherapy Clinical Trials
Our success in personalized cellular therapy does not stop with leukemia. We are continuing to develop and test cancer vaccines, immune modulatory drugs and cell based therapies for both blood and solid tumor cancers.
There are a number of CAR T clinical trials available at Penn Medicine, and they continue to be an area of priority for our researchers and clinicians. Find out if there is a clinical trial right for you.
To learn more about what clinical trials are, watch our video What is A Clinical Trial?
The Abramson Cancer Center's dynamic research program is always growing. Major areas of focus for immunotherapy research include CAR T therapy, vaccine therapy and checkpoint inhibitors.
Immune Cells Killed Doug's Cancer
For 20 years, Doug Olson lived with an enemy determined to take his life: chronic lymphocytic leukemia or CLL, a cancer that starts in the bone marrow. Over 14 years, Doug endured four rounds of conventional chemotherapy to control his CLL. But the cancer was relentless and progressing.
His oncologist, David Porter, MD, suggested something revolutionary and that's when he learned about the immunotherapy research study.
Read more about Doug's story
Parker Institute for Cancer Immunotherapy
Penn was one of six top medical institutions chosen to form the Parker Institute for Cancer Immunotherapy. The mission is to accelerate breakthrough immune therapies to turn cancer into a curable disease. It brings together the top minds in cancer to share ideas and findings.
Penn's success with leukemia has led to breakthroughs in myeloma and work in solid tumor cancers, diabetes, cardiology and Parkinson's - and will eventually extend to many diseases.
Latest News Releases
Penn Immunotherapy in the News